SynthesisInfection2026
Efficacy of fluoroquinolone prophylaxis in high-risk neutropenic patients with haematological malignancies: a systematic review with meta-analysis.
Synthesis in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the clinical and microbiological outcomes of high-risk neutropenic patients receiving or not fluoroquinolone prophylaxis. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials (RCTs) and observational studies investigating overall mortality and rate of febrile episodes, of bloodstream infections and of isolation of a fluoroquinolone-resistant strain among patients receiving or not prophylaxis.
participantsPatients with high-risk neutropenia due to haematological malignancies.
interventionsProphylaxis with either ciprofloxacin or levofloxacin. COMPARATOR: No prophylaxis. METHODS OF DATA SYNTHESIS: We conducted a meta-analysis pooling risk ratios (RRs) through random effect models.
resultsAmong 1731 articles screened, 18 original studies fulfilled the inclusion criteria and were included in the analysis, accounting for a total of 12,586 patients, 7157 (56.9%) of which receiving fluoroquinolones prophylaxis. The analysis assessing the primary outcome including 12,134 patients showed similar mortality rates between groups (RR 1.04, 95% CI 0.79-1.37, p = 0.77), with a low statistical heterogeneity observed (I
conclusionsOur data suggest that fluoroquinolone prophylaxis in high-risk neutropenic patients is associated with a reduction in the incidence of febrile episodes and bacteraemia but does not provide a survival benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.